Literature DB >> 6692517

The effects of antithrombotic drugs in patients with left ventricular thrombi: assessment with indium-111 platelet imaging and two-dimensional echocardiography.

J R Stratton, J L Ritchie.   

Abstract

Patients with left ventricular thrombi not caused by recent myocardial infarction were prospectively studied by indium-111 platelet imaging and two-dimensional echocardiography to determine the reproducibility of these techniques and the short-term effects of sulfinpyrazone (200 mg four times daily), aspirin (325 mg three times daily) plus dipyridamole (75 mg three times daily), and full-dose warfarin. At baseline, all patients underwent indium-111 platelet imaging and echocardiography, and the results were positive for thrombus. In six patients on no antithrombotic drug therapy, repeat platelet scans and echocardiographic studies at 6.0 +/- 3.3 weeks remained positive and were unchanged. In seven patients studied on sulfinpyrazone, three platelet scans became negative, two became equivocal, and two were unchanged; the presence and size of thrombus was constant by echocardiography in all seven patients. Of the six patients studied on aspirin plus dipyridamole, one platelet scan became negative, those of three became equivocal, and two were unchanged; all echocardiographic findings remained positive, but one patient had decreased thrombus size. Among four warfarin-treated patients, three had resolution of platelet deposition and one was unchanged; by echocardiography, thrombus resolved in one patient, was decreased in size in one, and was unchanged in two. We conclude that, in the absence of antithrombotic drug therapy, platelet imaging and echocardiographic findings are stable in patients with left ventricular thrombi not caused by recent myocardial infarction. Sulfinpyrazone, aspirin plus dipyridamole, and warfarin all interrupt platelet deposition in some patients with chronic left ventricular thrombi.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692517     DOI: 10.1161/01.cir.69.3.561

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

Review 1.  Common causes of cardiac emboli--left ventricular thrombi and atrial fibrillation.

Authors:  J R Stratton
Journal:  West J Med       Date:  1989-08

2.  Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care.

Authors:  M K Kapral; F L Silver
Journal:  CMAJ       Date:  1999-10-19       Impact factor: 8.262

Review 3.  An unmet clinical need: The history of thrombus imaging.

Authors:  Gregory M Lanza; Grace Cui; Anne H Schmieder; Huiying Zhang; John S Allen; Michael J Scott; Todd Williams; Xiaoxia Yang
Journal:  J Nucl Cardiol       Date:  2017-06-12       Impact factor: 5.952

4.  Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era.

Authors:  T Mooe; D Teien; K Karp; P Eriksson
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

5.  Availability of 111In-labeled platelet scintigraphy in patients with postinfarction left ventricular aneurysm.

Authors:  T Tsuda; M Kubota; A Iwakubo; H Akiba; M Shido; T Takahashi; T Nakata; T Noto; S Tanaka; O Iimura
Journal:  Ann Nucl Med       Date:  1989-03       Impact factor: 2.668

6.  Detection of ventricular thrombosis in acute myocardial infarction: value of indium-111 platelet scintigraphy in relation to two-dimensional echocardiography and clinical course.

Authors:  A J Küpper; F W Verheugt; W Jaarsma; E E van der Wall; M J van Eenige; W den Hollander; J P Roos
Journal:  Eur J Nucl Med       Date:  1986

7.  Left ventricular platelet deposition after acute myocardial infarction. An attempt at quantification using blood pool subtracted indium-111 platelet scintigraphy.

Authors:  F W Verheugt; J Lindenfeld; D L Kirch; P P Steele
Journal:  Br Heart J       Date:  1984-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.